LUKAS SCHEIBLER - 21 Apr 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: CHIEF INNOVATION OFFICER
Signature: /s/ David Watson, attorney-in-fact for Lukas Scheibler
Issuer symbol: APLS
Transactions as of: 21 Apr 2022
Net transactions value: -$430,000
Form type: 4
Filing time: 31 May 2022, 16:30:18 UTC
Previous filing: 06 Apr 2022
Next filing: 17 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Other	$0	-1,875	-3.6%	$0.000000	50,358	21 Apr 2022	Direct	F1
transaction	APLS	Common Stock	Sale	$430,000	-10,000	-20%	$43.00	40,358	27 May 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Other	$0	-11,250	-100%	$0.000000^*	0	21 Apr 2022	Common Stock	11,250	$44.90	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
F2	This is a scheduled sale from 10B5-1 trading plan.
F3	This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
F4	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.